Journal of medical economics · 2026
Cost-effectiveness of multitarget stool DNA testing for colorectal cancer screening in Chinese primary healthcare settings: a modelling study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Su Hang, Li Jingyi, Zhang Xinyi, Xiu Zhihui, Ge Tongtong, Tang Ning, Du Xue, Jiang Ruijingfang, Li Sha, Zhang Jing, Wei Ting, Xu Lizheng, Zhu Shida, Si Lei, Tian Maoyi
Аннотация
AIM: To evaluate the cost-effectiveness of a one-time mt-sDNA-based colorectal cancer screening program compared with no screening, using real-world data from a government-led population-based screening program in Harbin Municipality of China.
METHODS: This modelling study was based on a real-world mt-sDNA CRC screening program in Chinese primary healthcare settings. The program targeted residents aged 45-64 years without a prior history of CRC. A decision analytic model was developed from the healthcare system perspective to compare mt-sDNA screening with a hypothetical no-screening scenario. Costs included mt-sDNA testing, diagnostic colonoscopy after positive results, adenoma resection, and colorectal cancer treatment by disease stage. Effectiveness was measured in quality-adjusted life-years (QALYs). The primary outcome was the incremental cost-effectiveness ratio (ICER), assessed against a willingness-to-pay threshold of CNY 166,744 per QALY gained. Costs and QALYs were discounted at 5% annually over a lifetime horizon. One-way deterministic sensitivity analysis and probabilistic sensitivity analysis with 10,000 simulations were conducted.
RESULTS: Among 749,517 participants, 79,169 had positive mt-sDNA results and 17,364 completed diagnostic colonoscopy, corresponding to a colonoscopy adherence rate of 21.93%. In the base-case analysis, mt-sDNA screening incurred CNY 264 higher lifetime costs and yielded an additional 0.006 QALYs per person versus no screening. The mt-sDNA screening was cost-effective with an ICER of CNY 43,627 per QALY gained. The cost-effectiveness results were particularly sensitive to colonoscopy adherence (ranging from CNY 94,907 to 10,037 per QALY as adherence varied from 10% to 100%) and to the unit cost of the mt-sDNA test (ranging from CNY 22,113 to 65,140 per QALY with a ± 50% variation in cost). All ICERs remained below the cost-effectiveness threshold.
CONCLUSIONS: The mt-sDNA screening is cost-effective compared to no screening. These findings provide economic evidence to support the large-scale adoption of mt-sDNA-based screening in China.
METHODS: This modelling study was based on a real-world mt-sDNA CRC screening program in Chinese primary healthcare settings. The program targeted residents aged 45-64 years without a prior history of CRC. A decision analytic model was developed from the healthcare system perspective to compare mt-sDNA screening with a hypothetical no-screening scenario. Costs included mt-sDNA testing, diagnostic colonoscopy after positive results, adenoma resection, and colorectal cancer treatment by disease stage. Effectiveness was measured in quality-adjusted life-years (QALYs). The primary outcome was the incremental cost-effectiveness ratio (ICER), assessed against a willingness-to-pay threshold of CNY 166,744 per QALY gained. Costs and QALYs were discounted at 5% annually over a lifetime horizon. One-way deterministic sensitivity analysis and probabilistic sensitivity analysis with 10,000 simulations were conducted.
RESULTS: Among 749,517 participants, 79,169 had positive mt-sDNA results and 17,364 completed diagnostic colonoscopy, corresponding to a colonoscopy adherence rate of 21.93%. In the base-case analysis, mt-sDNA screening incurred CNY 264 higher lifetime costs and yielded an additional 0.006 QALYs per person versus no screening. The mt-sDNA screening was cost-effective with an ICER of CNY 43,627 per QALY gained. The cost-effectiveness results were particularly sensitive to colonoscopy adherence (ranging from CNY 94,907 to 10,037 per QALY as adherence varied from 10% to 100%) and to the unit cost of the mt-sDNA test (ranging from CNY 22,113 to 65,140 per QALY with a ± 50% variation in cost). All ICERs remained below the cost-effectiveness threshold.
CONCLUSIONS: The mt-sDNA screening is cost-effective compared to no screening. These findings provide economic evidence to support the large-scale adoption of mt-sDNA-based screening in China.